Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,865 matching trials from the live ClinicalTrials.gov search.

Filters: Chapel Hill, North Carolina Clear all

Conditions: Neuroblastoma
Interventions: carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, Isotretinoin, Surgery, Filgrastim; Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 12 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 166
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 137 more

Conditions: Colon, Irritable
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions: Bevacizumab, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 1,873 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 614
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 395 more

Conditions: Melanoma
Interventions: Ipilimumab, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 36
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 26 more

Conditions: Sickle Cell Disease
Interventions: Single blood transfusion, Standard care; Biological · Behavioral
Lead sponsor: Carelon Research; Other
Eligibility: 2 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 14 more

Conditions: Knee Osteoarthritis
Interventions: Transcutaneous Electrical Nerve Stimulation, Therapeutic Exercise, Sham Transcutaneous Electrical Nerve Stimulation; Device · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Melanoma, Cutaneous Malignant, Mucosal Melanoma
Interventions: IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel; Biological · Drug
Lead sponsor: Immatics US, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 43
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more

Conditions: Barrett Esophagus
Interventions: Potassium-Competitive Acid Blockers (PCABs); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hematopoietic Stem Cell Transplantation, Delirium, Thiamine Deficiency
Interventions: Thiamine, Normal saline; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Barrett's Esophagus
Interventions: trūFreeze™ Spray Cryotherapy; Device
Lead sponsor: CSA Medical, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Jacksonville, Florida • Baltimore, Maryland • New York, New York + 3 more

Conditions: Leukemia
Interventions: cytarabine, daunorubicin, midostaurin, placebo, dexamethasone acetate; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 59 Years
Enrollment: 717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2022
U.S. locations: 170
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 126 more

Conditions: Turner Syndrome
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 2 Weeks to 2 Years
Enrollment: 295 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Lymphoma
Interventions: doxorubicin hydrochloride, gemcitabine hydrochloride, vinblastine, fludeoxyglucose F 18 positron-emission tomography (PET) scan, CT scan; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 16 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 47
States / cities: San Francisco, California • Lewes, Delaware • Newark, Delaware + 32 more

Conditions: Chronic Kidney Disease, Congenital Anomalies of Kidney and Urinary Tract
Interventions: Renal Autologous Cell Therapy (REACT); Biological
Lead sponsor: Prokidney; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: Atlanta, Georgia • Meridian, Idaho • Neptune City, New Jersey + 2 more

Conditions: Plasminogen Deficiency
Interventions: Not listed
Lead sponsor: Indiana Hemophilia &Thrombosis Center, Inc.; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 13
States / cities: Birmingham, Alabama • Chicago, Illinois • Indianapolis, Indiana + 10 more

Conditions: Sickle Cell Disease
Interventions: High Demand / Low Infusion, PCA Dosing Plan; Other
Lead sponsor: Carelon Research; Other
Eligibility: 10 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 28
States / cities: Oakland, California • New Haven, Connecticut • Wilmington, Delaware + 18 more

Conditions: Breast Cancer
Interventions: 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Pertuzumab, Placebo, Trastuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 4,804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 114
States / cities: Scottsdale, Arizona • Everett, California • Greenbrae, California + 92 more

Conditions: Nutrition, Health, Dietary Habits
Interventions: Diet A, Diet B, Diet C; Other
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • Davis, California • Los Angeles, California + 7 more

Conditions: Crohn Disease
Interventions: Etrolizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 62
States / cities: Arcadia, California • La Jolla, California • Long Beach, California + 53 more

Conditions: Osteoporosis, Rheumatoid Arthritis
Interventions: Tailored Materials, Tailored Materials Plus Physician Feedback, Generic Materials, No Information; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Communication, Trust, Covid19, Surgery
Interventions: Transparent mask, Typical surgical covered mask; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HER2-positive Breast Cancer
Interventions: Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 40 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2037
U.S. locations: 413
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 286 more

Conditions: HIV
Interventions: Epic Allies App Intervention, Epic Allies - Control Branch; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years · Male only
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 5
States / cities: Tampa, Florida • Chicago, Illinois • New Orleans, Louisiana + 2 more

Conditions: Nutrition, Physical Activity
Interventions: Intervention Physical Activity, Usual Care; Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

Preventing Acute Chest Syndrome by Transfusion Feasibility Study

The KNEEhabilitation Study: Improving Disability in Individuals With Knee Osteoarthritis

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study)

High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation

A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Sex Differences in Early Brain Development; Brain Development in Turner Syndrome

Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma

A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).

Study of Individuals Affected With Hypoplasminogenemia

THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Nutrition for Precision Health, Powered by the All of Us

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease

GIOP Prevention Among People With Rheumatoid Arthritis

The Effect of Clear Masks in Improving Patient Relationships

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

Epic Allies HIV ART Adherence Intervention

A Web-based Tailored Health Behavior Intervention for Breast and Colon Cancer Survivors (eWellness)